» Articles » PMID: 25207151

Sentinel Lymph Node Biopsy in Breast Cancer: Predictors of Axillary and Non-sentinel Lymph Node Involvement

Overview
Journal Balkan Med J
Specialty General Medicine
Date 2014 Sep 11
PMID 25207151
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sentinel lymph node biopsy is a standard method for the evaluation of axillary status in patients with T1-2N0M0 breast cancers.

Aims: To determine the prognostic significance of primary tumour-related clinico-histopathological factors on axillary and non-sentinel lymph node involvement of patients who underwent sentinel lymph node biopsy.

Study Design: Retrospective clinical study.

Methods: In the present study, 157 sentinel lymph node biopsies were performed in 151 consecutive patients with early stage breast cancer between June 2008 and December 2011.

Results: Successful lymphatic mapping was obtained in 157 of 158 procedures (99.4%). The incidence of larger tumour size (2.543±1.21 vs. 1.974±1.04), lymphatic vessel invasion (70.6% vs. 29.4%), blood vessel invasion (84.2% vs. 15.8%), and invasive lobular carcinoma subtype (72.7% vs. 27.3%) were statistically significantly higher in patients with positive SLNs. Logistic stepwise regression analysis disclosed tumour size (odds ratio: 1.51, p=0.0021) and lymphatic vessel invasion (odds ratio: 4.68, p=0.001) as significant primary tumour-related prognostic determinants of SLN metastasis.

Conclusion: A close relationship was identified between tumour size and lymphatic vessel invasion of the primary tumour and axillary lymph node involvement. However, the positive predictive value of these two independent variables is low and there is no compelling evidence to recommend their use in routine clinical practice.

Citing Articles

Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla.

Chinnappan S, Chandra P, Kumar S, Sridev M, Jain D, Chandran G World J Nucl Med. 2022; 21(2):120-126.

PMID: 35865159 PMC: 9296246. DOI: 10.1055/s-0042-1750333.


Impact of Size of the Tumour, Persistence of Estrogen Receptors, Progesterone Receptors, HER2Neu Receptors and Ki67 Values on Positivity of Axillary Lymph Nodes in Patients with Early Breast Cancer with Clinically Negative Axillary Examination.

Kondov B, Isijanovska R, Milenkovikj Z, Petrusevska G, Jovanovski-Srceva M, Bogdanovska-Todorovska M Open Access Maced J Med Sci. 2018; 5(7):825-830.

PMID: 29362604 PMC: 5771280. DOI: 10.3889/oamjms.2017.213.


Determinants of lymph node status in women with breast cancer: A hospital based study from eastern India.

Chakraborty A, Bose C, Basak J, Sen A, Mishra R, Mukhopadhyay A Indian J Med Res. 2016; 143(Supplement):S45-S51.

PMID: 27748277 PMC: 5080928. DOI: 10.4103/0971-5916.191761.


Tumour location within the breast: Does tumour site have prognostic ability?.

Rummel S, Hueman M, Costantino N, Shriver C, Ellsworth R Ecancermedicalscience. 2015; 9:552.

PMID: 26284116 PMC: 4531129. DOI: 10.3332/ecancer.2015.552.


Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.

Jiwa L, van Diest P, Hoefnagel L, Wesseling J, Wesseling P, Moelans C BMC Cancer. 2014; 14:864.

PMID: 25417118 PMC: 4247109. DOI: 10.1186/1471-2407-14-864.

References
1.
van der Heiden-van der Loo M, Schaapveld M, Ho V, Siesling S, Rutgers E, Peeters P . Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. Ann Oncol. 2013; 24(11):2794-801. DOI: 10.1093/annonc/mdt243. View

2.
Kell M, Burke J, Barry M, Morrow M . Outcome of axillary staging in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010; 120(2):441-447. DOI: 10.1007/s10549-009-0705-6. View

3.
Dowlatshahi K, Fan M, Snider H, Habib F . Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer. 1997; 80(7):1188-97. DOI: 10.1002/(sici)1097-0142(19971001)80:7<1188::aid-cncr2>3.0.co;2-h. View

4.
Schwartz G . Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J. 2004; 10(2):85-8. DOI: 10.1111/j.1075-122x.2004.21439.x. View

5.
Giuliano A, McCall L, Beitsch P, Whitworth P, Blumencranz P, Leitch A . Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010; 252(3):426-32. PMC: 5593421. DOI: 10.1097/SLA.0b013e3181f08f32. View